Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Antitumor Effect of Everolimus in a Patient with Type 3 Gastric Neuroendocrine Tumor
Author: Bariani, GM
Carvalheira, JB
Riechelmann, RP
Abstract: Background: Gastric neuroendocrine tumors (NET) are rare and are classified into 3 types: type 1 and 2 (characterized by hypergastrinemia), and type 3 (characterized by normal gastrin). Surgery is the standard procedure, and systemic treatment is reserved for unresectable disease. Currently, targeted therapies are being evaluated in NET. The activity of everolimus, an mTOR inhibitor, has been shown in pancreatic NET but not reported in type 3 gastric carcinoid tumors. Case Report: Here we report a case of a patient who, after multiple lines of systemic therapy, had a prolonged disease control of nearly 1 year, significant clinical benefit, and minor tumor shrinkage with oral everolimus 10 mg continuously. Conclusion: There is no effective treatment for type 3 gastric carcinoid tumors. The frequency of mTOR expression in these tumors is not known, but the case reported here suggests that inhibition of this pathway may play an important role.
Subject: Stomach neoplasms
Carcinoid tumor
Molecular targeted therapy
Country: Suíça
Editor: Karger
Rights: fechado
Identifier DOI: 10.1159/000354637
Date Issue: 2013
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.